ProQR Therapeutics N.V. (PRQR) — Analyst outlook / Analyst consensus target is. Based on 10 analyst ratings, the consensus is bullish — 1 Strong Buy, 8 Buy, 1 Hold.
The consensus price target is $3.63 (low: $2.00, high: $5.00), representing an upside of 82.4% from the current price $1.99.
Analysts estimate Earnings Per Share (EPS) of $-0.33 and revenue of $0.02B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.34 vs est $-0.33 (missed -2%). 2025: actual $-0.38 vs est $-0.41 (beat +6.5%). Analyst accuracy: 96%.
PRQR Stock — 12-Month Price Forecast
$3.63
▲ +82.41% Upside
Average Price Target
Based on 10 Wall Street analysts offering 12-month price targets for ProQR Therapeutics N.V., the average price target is $3.63, with a high forecast of $5.00, and a low forecast of $2.00.
The average price target represents a +82.41% change from the last price of $1.99.
Highest Price Target
$5.00
Average Price Target
$3.63
Lowest Price Target
$2.00
PRQR Analyst Ratings
Buy
Based on 10 analysts giving stock ratings to ProQR Therapeutics N.V. in the past 3 months
EPS Estimates — PRQR
96%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$0.34
vs Est –$0.33
▼ 2.0% off
2025
Actual –$0.38
vs Est –$0.41
▲ 7.0% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — PRQR
93%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.019B
vs Est $0.017B
▲ 7.7% off
2025
Actual $0.015B
vs Est $0.016B
▼ 6.3% off
Revenue Trend
Revenue has declined over the period shown. Analysts expect stable revenue going forward.
